The estimated Net Worth of Steve O'loughlin is at least $512 mil dollars as of 10 December 2018. Mr. loughlin owns over 10,000 units of Actinium Pharmaceuticals Inc stock worth over $69,225 and over the last 7 years he sold ATNM stock worth over $0. In addition, he makes $442,914 as Principal Financial and Accounting Officer at Actinium Pharmaceuticals Inc.
Steve has made over 2 trades of the Actinium Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of ATNM stock worth $4,400 on 10 December 2018.
The largest trade he's ever made was buying 12,000 units of Actinium Pharmaceuticals Inc stock on 15 June 2018 worth over $6,000. On average, Steve trades about 2,444 units every 20 days since 2018. As of 10 December 2018 he still owns at least 35,500 units of Actinium Pharmaceuticals Inc stock.
You can see the complete history of Mr. loughlin stock trades at the bottom of the page.
Steve O'Loughlin serves as Principal Financial and Accounting Officer of the Company. Mr. O’Loughlin joined Actinium in October 2015 as Vice President, Finance and Corporate Development, with almost a decade of life sciences industry experience gained from previous positions in investment banking and publicly traded life sciences companies. Prior to Actinium, from June 2015 to October 2015, Mr. O’Loughlin worked at J. Streicher LLC as an investment banker, from August 2012 to June 2015 Mr. O’Loughlin held the position of Vice President, Corporate Finance and Development and was a corporate officer at Protea Biosciences, Inc., a publicly traded life sciences tools company. Previously, From June 2010 to June 2012, Mr. O’Loughlin held corporate development positions with Caliber I.D., a publicly traded diagnostics company. Mr. O’Loughlin previously worked in investment banking at Jesup & Lamont where he focused on the biotechnology and life sciences industries. Mr. O’Loughlin has a B.S. in Business Administration with a concentration in finance from Ramapo College of New Jersey.
As the Principal Financial and Accounting Officer of Actinium Pharmaceuticals Inc, the total compensation of Steve Loughlin at Actinium Pharmaceuticals Inc is $442,914. There are 4 executives at Actinium Pharmaceuticals Inc getting paid more, with Sandesh Seth having the highest compensation of $1,102,720.
Steve Loughlin is 35, he's been the Principal Financial and Accounting Officer of Actinium Pharmaceuticals Inc since 2017. There are 8 older and no younger executives at Actinium Pharmaceuticals Inc. The oldest executive at Actinium Pharmaceuticals Inc is Ajit Shetty, 73, who is the Independent Director.
Steve's mailing address filed with the SEC is C/O ACTINIUM PHARMACEUTICALS, INC.,, 100 PARK AVE., 23RD FLOOR, NEW YORK,, NY, 10017.
Over the last 7 years, insiders at Actinium Pharmaceuticals Inc have traded over $0 worth of Actinium Pharmaceuticals Inc stock and bought 79,730 units worth $38,874 . The most active insiders traders include Anil Kapur, Ajit Shetty y Sandesh Seth. On average, Actinium Pharmaceuticals Inc executives and independent directors trade stock every 41 days with the average trade being worth of $22,211. The most recent stock trade was executed by Sandesh Seth on 10 December 2018, trading 10,000 units of ATNM stock currently worth $4,400.
actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. the company’s lead radiopharmaceutical iomab™-b will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. the company is preparing a single, pivotal, multicenter phase 3 clinical study of iomab™-b in refractory and relapsed acute myeloid leukemia (aml) patients over the age of 55 with a primary endpoint of durable complete remission. the company’s second program, actimab-a, is continuing its clinical development in a phase 1/2 trial for newly diagnosed aml patients o
Actinium Pharmaceuticals Inc executives and other stock owners filed with the SEC include: